ECO-CLIN URINAL TABLETS

Glavne informacije

  • Zaščiteno ime:
  • ECO-CLIN URINAL TABLETS
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • ECO-CLIN URINAL TABLETS
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 113462E
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

1 / 15

ODDELEK 1: Identifikacija snovi/zmesi in družbe/podjetja

1.1 Identifikator izdelka

Ime proizvoda

Eco-clin urinal tablets

Koda proizvoda

113462E

Uporaba snovi/zmesi

Čistilo za sanitarije

Vrsta snovi

Zmes

Samo za poklicne uporabnike.

Podatki o redčenju izdelka

Podatkov o redčenju ni na voljo.

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Identifikacija uporabe

Čistilo za sanitarije. Ročni postopek

Priporočene omejitve

uporabe

Samo za industrijsko in profesionalno uporabo.

1.3 Podrobnosti o dobavitelju varnostnega lista

Družba

Ecolab d.o.o.

Vajngerlova ulica 4

2000, Maribor Slovenija 02 429 3100 (Delavnik: 8:00 - 16:00)

narocila@ecolab.com

1.4 Telefonska številka za nujne primere

Telefonska številka za nujne

primere

02 429 3100 (Delavnik: 8:00 - 16:00)

Telefonska številka Centra

za zastrupitve

Datum sestavitve/Revizije

09.07.2015

Verzija

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Razvrstitev (UREDBA (ES) št. 1272/2008)

Draženje kože, Kategorija 2

H315

Huda poškodba oči, Kategorija 1

H318

Kronična strupenost za vodno okolje, Kategorija 3

H412

Razvrstitev (67/548/EGS, 1999/45/ES)

Xn; ZDRAVJU ŠKODLJIVO

R52/53

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

2 / 15

Popolno besedilo stavkov 'R' omenjenih v tem Poglavju, je v Poglavju 16.

Za celotno besedilo H-izjav, omenjeno v tem poglavju, glej 16. poglavje.

2.2 Elementi etikete

Etiketiranje (UREDBA (ES) št. 1272/2008)

Piktogrami za nevarnost

Opozorilna beseda

Nevarno

Opozorila o nevarnosti

H315

Povzroča draženje kože

H318

Povzroča hude poškodbe oči.

H412

Škodljivo za vodne organizme, z dolgotrajnimi

učinki.

Obvestila o nevarnosti

Preprečevanje:

P273

Preprečiti sproščanje v okolje.

P280

Nositi zaščitne rokavice/ zaščito za oči/ zaščito

za obraz.

Ukrepanje:

P305 + P351 + P338

PRI STIKU Z OČMI: previdno izpirajte z

vodo nekaj minut. Odstranite kontaktne leče,

če jih imate in če to lahko storite brez težav.

Nadaljujte z izpiranjem.

P310

Takoj pokličite CENTER ZA

ZASTRUPITVE/zdravnika.

Nevarne komponente, ki morajo biti naštete na nalepki/etiketi:

Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

2.3 Druge nevarnosti

Ne mešati z belilom ali kakim drugim sredstvom, ki vsebuje klor – lahko pride do sproščanja klora.

ODDELEK 3: Sestava/podatki o sestavinah

3.2 Zmesi

Nevarne sestavine

Kemijsko ime

Št. CAS

ES-št.

Št. REACH

Razvrstitev

(67/548/EGS)

Razvrstitev

(UREDBA (ES) št.

1272/2008)

Koncentracija:

Natrijev karbonat

(soda)

497-19-8

207-838-8

01-2119485498-19

Xi; R36

Draženje oči Kategorija 2;

H319

>= 30 - < 50

Benzensulfonska

kislina, C10-13-alkil

derivati, natrijeve soli

68411-30-3

270-115-0

01-2119489428-22

Xn-Xi; R22-

R38-R41-

R52/53

Akutna strupenost Kategorija

4; H302

Draženje kože Kategorija 2;

H315

Huda poškodba oči Kategorija

>= 25 - < 30

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

3 / 15

1; H318

Kronična strupenost za vodno

okolje Kategorija 3; H412

Alkiletersulfati

68891-38-3

500-234-8

01-2119488639-16

Xi; R38-R41

Draženje kože Kategorija 2;

H315

Huda poškodba oči Kategorija

1; H318

>= 3 - < 5

citronska kislina

77-92-9

201-069-1

Xi; R36

Jedko za kovine Kategorija 1;

H290

Draženje oči Kategorija 2;

H319

>= 3 - < 5

pine, ext.

94266-48-5

304-455-9

Xn; R65

Xi; R36

N; R51/53

Draženje oči Kategorija 2;

H319

Nevarnost pri vdihavanju

Kategorija 1; H304

Kronična strupenost za vodno

okolje Kategorija 1; H410

>= 1 - < 2.5

Popolno besedilo stavkov 'R' omenjenih v tem Poglavju, je v Poglavju 16.

Za celotno besedilo H-izjav, omenjeno v tem poglavju, glej 16. poglavje.

ODDELEK 4: Ukrepi za prvo pomoč

4.1 Opis ukrepov za prvo pomoč

Pri stiku z očmi

Takoj začeti izpirati z obilo vode, tudi pod očesnim vekam,

najmanj 15 minut. Odstranite kontaktne leče, če jih imate in če to

lahko storite brez težav. Nadaljujte z izpiranjem. Takoj pokličite

zdravnika.

Pri stiku s kožo

Takoj umivajte/izpirajte z obilo vode vsaj 15 minut. Po možnosti

uporabljati blago milo. Če se draženje razvije in ne preneha,

poiskati zdravniško pomoč.

Pri zaužitju

Splaknite usta. Če se pojavijo simptomi, poiskati zdravniško

pomoč.

Pri vdihavanju

Potrebna je odstranitev na svež zrak. Simptomatsko zdravljenje.

Če se pojavijo simptomi, poiskati zdravniško pomoč.

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptome.

4.3 Navedba kakršnekoli takojšnje medicinske oskrbe in posebnega zdravljenja

Oskrba, obdelava

Simptomatsko zdravljenje.

ODDELEK 5: Protipožarni ukrepi

5.1 Sredstva za gašenje

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

4 / 15

Ustrezna sredstva za

gašenje:

Uporabljajte gasilne ukrepe, ki so primerni lokalnim okoliščinam in

bližnjemu okolju.

Neustrezna sredstva za

gašenje

Nobena znana.

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

Specifične nevarnosti med

gašenjem

Ni vnetljivo ali gorljivo.

Nevarni proizvodi izgorevanja

Razkrojni produkti lahko vsebujejo naslednje snovi:

Ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforovi oksidi

5.3 Nasvet za gasilce

Posebne varovalne opreme

za gasilce

: Uporabljajte osebno varovalno opremo.

Dodatne informacije

: Ostanke po požaru in kontaminirano vodo za gašenje požara je

treba varno odstraniti v skladu z lokalnimi uredbami. Pri požaru

in/ali eksploziji ne vdihavajte dima.

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

Nasvet za neizučeno osebje

Zagotovite zadostno prezračevanje. Preprečite ljudem dostop do

izpusta/razliva in v protivetrni smeri od izpusta/razliva. Izogibati se

vdihavanju, zaužitju ter stiku s kožo in očmi. Če so delavci

izpostavljeni koncentracijam nad dovoljenimi mejnimi vrednostmi,

morajo uporabljati ustrezno obrazno masko. Zagotovite, da

cišcenje izvaja samo usposobljeno osebje. Informirajte se o

varnostnih ukrepih, naštetih v poglavjih 7 in 8.

Nasvet za reševalce

Če so pri rokovanju z razlitjem zahtevana specialna oblačila,

upoštevati podatke o primernih in neprimernih materialih v

Oddelku 8.

6.2 Okoljevarstveni ukrepi

Okoljevarstveni ukrepi

Preprečiti, da pride v stik z zemljo, površinsko vodo ali podtalnico.

6.3 Metode in materiali za zadrževanje in čiščenje

Metodah za čiščenja

Pometite in naložite z lopato v primerne odlagalne vsebnike.

6.4 Sklicevanje na druge oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Za osebno zaščito glejte poglavje 8.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

ODDELEK 7: Ravnanje in skladiščenje

7.1 Varnostni ukrepi za varno ravnanje

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

5 / 15

Navodilo za varno rokovanje

Preprečiti stik s kožo in očmi. Preprečiti stik z očmi, kožo ali

oblačili. Ne vdihavati prahu/ dima/ plina/ meglice/ hlapov/

razpršila. Uporabljati samo ob ustreznem prezračevanju. Po

uporabi temeljito umiti roke. Ne mešati z belilom ali kakim drugim

sredstvom, ki vsebuje klor – lahko pride do sproščanja klora.

Higienski ukrepi

Ravnajte v skladu z dobro industrijsko higiensko in varnostno

prakso. Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

7.2 Pogoji za varno skladiščenje, vključno z nezdružljivostjo

Zahteve glede skladiščnih

področij in vsebnikov

Hraniti zunaj dosega otrok. Hraniti v tesno zaprti posodi. Hraniti v

posodah z ustreznimi nalepkami.

Temperatura pri skladiščenju

-5 °C do 40 °C

7.3 Posebne končne uporabe

Posebni način(-i) uporabe

Čistilo za sanitarije. Ročni postopek

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Mejne vrednosti za poklicno izpostavljenost

Ne vsebuje sestavin z mejnimi vrednostmi za poklicno izpostavljenost.

DNEL

Natrijev karbonat (soda)

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni lokalni učinki

Vrednost: 10 mg/m3

Končna uporaba: Potrošniki

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Akutni lokalni učinki

Vrednost: 10 mg/m3

Benzensulfonska kislina,

C10-13-alkil derivati,

natrijeve soli

Končna uporaba: Delavci

Načini izpostavljenosti: Kožno

Potencialni učinki na zdravje: Dolgoročni sistemski učinki

Vrednost: 85 mg/cm2

Končna uporaba: Delavci

Načini izpostavljenosti: Kožno

Potencialni učinki na zdravje: Dolgoročni lokalni učinki

Vrednost: 85 mg/cm2

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni sistemski učinki

Vrednost: 6 mg/m3

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

6 / 15

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni lokalni učinki

Vrednost: 6 mg/m3

PNEC

Benzensulfonska kislina,

C10-13-alkil derivati,

natrijeve soli

Sladka voda

Vrednost: 0.268 mg/l

Morska voda

Vrednost: 0.0268 mg/l

Prekinjena uporaba/izpust

Vrednost: 0.0167 mg/l

Usedlina v sladki vodi

Vrednost: 8.1 mg/kg

Usedlina v morju

Vrednost: 8.1 mg/kg

Naprava za čiščenje odplak

Vrednost: 3.43 mg/l

8.2 Nadzor izpostavljenosti

Ustrezni inženirski mehanizmi

Tehnični ukrepi

Učinkovit izpušni prezračevalni sistem. Ohranjati vrednosti

koncentracij v zraku znotraj standardov za poklicno

izpostavljenost.

Individualni zaščitni ukrepi

Higienski ukrepi

Ravnajte v skladu z dobro industrijsko higiensko in varnostno

prakso. Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

Zaščito za oči / obraz (EN

166)

Varovalna očala

Obrazni ščitnik

Zaščita rok (EN 374)

Nosite naslednjo osebno zaščitno opremo:

Nitrilni kavčuk

butilni kavčuk

Neprepustne rokavice

Če se pojavijo kakršni koli znaki razkroja rokavic ali prodora

kemikalij skozi rokavice, je treba le-te odstraniti in jih zamenjati z

novimi.

Zaščita kože in telesa (EN

14605)

Ni potrebna posebna varovalna oprema.

Zaščita dihal (EN 143,

Ni potrebna, če se koncentracija nevarnih snovi v zraku ohrani

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

7 / 15

14387)

pod mejnimi vrednostmi, navedenimi v podatkih o mejnih

vrednostih izpostavitve. Uporabiti certificirano dihalno napravo,

skladno z zahtevami Direktiv 89/656/EGS in 89/686/EGS ali

enakovredno, kadar se tveganju za dihala ni mogoče izogniti s

tehničnimi varovalnimi sredstvi in ukrepi, metodami ali postopki

organizacije dela.

Nadzor izpostavljenosti okolja

Splošna navodila

: Upoštevati dolocilo o ograjevanju okoli posod za shranjevanje.

ODDELEK 9: Fizikalne in kemijske lastnosti

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Videz

: trdno

Barva

: svetlo zelena

Vonj

: lahen

10.0 - 11.0, 1 %

Plamenišče

Se ne upošteva.

Mejne vrednosti vonja

Ni primerno in/ali ni določeno za zmesi

Tališče/ledišče

Ni primerno in/ali ni določeno za zmesi

Začetno vrelišče in območje

vrelišča

Ni primerno in/ali ni določeno za zmesi

Hitrost izparevanja

Ni primerno in/ali ni določeno za zmesi

Vnetljivost (trdno, plinasto)

Ni primerno in/ali ni določeno za zmesi

Zgornja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Spodnja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Parni tlak

Ni primerno in/ali ni določeno za zmesi

Relativna gostota par/hlapov

Ni primerno in/ali ni določeno za zmesi

Relativna gostota

1.4 - 1.8

Topnost v vodi

topnost v maščobah

Topnost v drugih topilih

Ni primerno in/ali ni določeno za zmesi

Porazdelitveni koeficient: n-

oktanol/voda

Ni primerno in/ali ni določeno za zmesi

Temperatura samovžiga

Ni primerno in/ali ni določeno za zmesi

Toplotni razpad/razgradnja

Ni primerno in/ali ni določeno za zmesi

Viskoznost, kinematična

Ni primerno in/ali ni določeno za zmesi

Eksplozivne lastnosti

Ni primerno in/ali ni določeno za zmesi

Oksidativne lastnosti

Snov ali zmes ni označena kot oksidativna.

9.2 Drugi podatki

Ni primerno in/ali ni določeno za zmesi

ODDELEK 10: Obstojnost in reaktivnost

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

8 / 15

10.1 Reaktivnost

Nevarne reakcije pri normalni uporabi niso znane.

10.2 Kemijska stabilnost

Stabilno pri normalnih pogojih.

10.3 Možnost poteka nevarnih reakcij

Ne mešati z belilom ali kakim drugim sredstvom, ki vsebuje klor – lahko pride do sproščanja klora.

10.4 Pogoji, ki se jim je treba izogniti

Nobena znana.

10.5 Nezdružljivi materiali

Nobena znana.

10.6 Nevarni produkti razgradnje

Razkrojni produkti lahko vsebujejo naslednje snovi:

Ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforovi oksidi

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Podatki o možnih načinih

izpostavljenosti

Stik z očmi, Stik s kožo

Strupenost

Akutna oralna toksičnost

: Ocena akutne strupenosti : > 2,000 mg/kg

Akutna toksičnost pri

vdihavanju

: Za ta proizvod ni na voljo podatkov.

Akutno dermalno strupenost

: Za ta proizvod ni na voljo podatkov.

Jedkost za kožo/draženje

kože

: Za ta proizvod ni na voljo podatkov.

Resne okvare oči/draženje

: Za ta proizvod ni na voljo podatkov.

Preobčutljivost pri vdihavanju

in preobčutljivost kože

: Za ta proizvod ni na voljo podatkov.

Rakotvornost

: Za ta proizvod ni na voljo podatkov.

Učinki na razplojevanje

: Za ta proizvod ni na voljo podatkov.

Mutagenost za zarodne

: Za ta proizvod ni na voljo podatkov.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

9 / 15

celice

Teratogenost

: Za ta proizvod ni na voljo podatkov.

STOT - enkratna

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

STOT - ponavljajoča se

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

Toksičnost pri vdihavanju

: Za ta proizvod ni na voljo podatkov.

Komponente

Akutna oralna toksičnost

: Natrijev karbonat (soda)

LD50 Podgana: 2,800 mg/kg

Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

LD50 Podgana: 1,080 mg/kg

Alkiletersulfati

LD50 Podgana: 3,350 mg/kg

citronska kislina

LD50 Podgana: 11,700 mg/kg

pine, ext.

LD50 Podgana: 3,200 mg/kg

Komponente

Akutno dermalno strupenost

: Alkiletersulfati

LD50 Kunec: 8,000 mg/kg

pine, ext.

LD50 Kunec: > 5,000 mg/kg

Možni učinki na zdravje

Oči

Povzroča hude poškodbe oči.

Koža

Povzroča razdraženost kože.

Zaužitje

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Vdihavanje

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Kronična izpostavljenost

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Izkušnje z izpostavljenostjo človeka

Stik z očmi

Rdečina, Bolečina, Razjede

Stik s kožo

Rdečina, Draženje

Zaužitje

Ni znanih ali pričakovanih simptomov.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

10 / 15

Vdihavanje

Ni znanih ali pričakovanih simptomov.

ODDELEK 12: Ekološki podatki

12.1 Ekotoksičnost

Učinki na okolje

Škodljivo za vodne organizme, z dolgotrajnimi učinki.

Proizvod

Strupenost za ribe

: Ni razpoložljivih podatkov

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Ni razpoložljivih podatkov

Strupenost za alge

: Ni razpoložljivih podatkov

Komponente

Strupenost za ribe

: Natrijev karbonat (soda)

96 h LC50 Lepomis macrochirus (Sončni ostriž): 300 mg/l

Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

96 h LC50 Lepomis macrochirus (Sončni ostriž): 1.67 mg/l

Alkiletersulfati

96 h LC50 Ribe: 7.1 mg/l

citronska kislina

96 h LC50 Ribe: > 100 mg/l

Komponente

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Natrijev karbonat (soda)

48 h EC50 Ceriodaphnia (vodna bolha): 213.5 mg/l

Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

48 h LC50 Daphnia magna (Vodna bolha): 2.4 mg/l

Komponente

Strupenost za alge

: Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

96 h EC50 Pseudokirchneriella subcapitata (zelena alga): 29 mg/l

12.2 Obstojnost in razgradljivost

Proizvod

Biorazgradljivost

: V proizvodu vsebovane površinsko aktivne snovi so

biorazgradljive v skladu z Uredbo o detergentih 648/2004/EC.

Komponente

Biorazgradljivost

Natrijev karbonat (soda)

Rezultat: Se ne upošteva.

Benzensulfonska kislina, C10-13-alkil derivati, natrijeve soli

Rezultat: Zlahka biorazgradljivo.

Alkiletersulfati

Rezultat: Zlahka biorazgradljivo.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

11 / 15

citronska kislina

Rezultat: Zlahka biorazgradljivo.

pine, ext.

Rezultat: Se ne upošteva.

12.3 Zmožnost kopičenja v organizmih

Ni razpoložljivih podatkov

12.4 Mobilnost v tleh

Ni razpoložljivih podatkov

12.5 Rezultati ocene PBT in vPvB

Proizvod

Ocena

Snov/mešanica ne vsebuje komponent, ki so obstojne,

bioakumulacijske in strupene (PBT) ali izredno obstojne in zelo

bioakumulacijske (vPvB) v koncentracijah 0,1% ali več.

12.6 Drugi škodljivi učinki

Ni razpoložljivih podatkov

ODDELEK 13: Odstranjevanje

Odložiti v skladu z evropskimi direktivami o odpadkih in nevarnih odpadkih.Odpadkom naj bi kode

pripisal uporabnik, prednostno po posvetu z organi, ki so pristojni za odstranjevanje odpadkov.

13.1 Metode ravnanja z odpadki

Proizvod

: Preprečiti, da proizvod pride v kanalizacijo, vodotoke ali v zemljo.

Kjer je mogoče, ima recikliranje prednost pred odlaganjem ali

sežiganjem. Če recikliranje ni izvedljivo, odstranite v skladu z

lokalnimi uredbami. Odpad odlagajte v odobrenih objektih za

odlaganje odpada.

Kontaminirana

embalaža/pakiranje

: Odstranite kot nerabljen proizvod. Prazne posode je treba

dostaviti pooblaščeni osebi za ravnanje z odpadki na recikliranje

ali odlaganje. Prazni vsebniki niso za ponovno uporabo.

Odstranjevati v skladu s krajevnimi, državnimi in zveznimi

predpisi.

Evropski katalog odpadkov

: 200129* - čistila (detergenti), ki vsebujejo nevarne snovi

ODDELEK 14: Podatki o prevozu

Špediter/pošiljatelj/dobavitelj je odgovoren zagotoviti, da so embalaža, oznake in nalepke za

označevanje nevarnosti skladni z izbranim načinom prevoza.

Transport po kopnem (ADR/ADN/RID)

14.1 Številka ZN

Nenevarno blago

14.2 Pravilno odpremno ime

Nenevarno blago

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

12 / 15

14.3 Razredi nevarnosti

prevoza

Nenevarno blago

14.4 Skupina embalaže

Nenevarno blago

14.5 Nevarnosti za okolje

Nenevarno blago

14.6 Posebni previdnostni

ukrepi za uporabnika

Nenevarno blago

Zračni transport (IATA)

14.1 Številka ZN

Nenevarno blago

14.2 Pravilno odpremno ime

Nenevarno blago

14.3 Razredi nevarnosti

prevoza

Nenevarno blago

14.4 Skupina embalaže

Nenevarno blago

14.5 Nevarnosti za okolje

Nenevarno blago

14.6 Posebni previdnostni

ukrepi za uporabnika

Nenevarno blago

Pomorski transport

(IMDG/IMO)

14.1 Številka ZN

Nenevarno blago

14.2 Pravilno odpremno ime

Nenevarno blago

14.3 Razredi nevarnosti

prevoza

Nenevarno blago

14.4 Skupina embalaže

Nenevarno blago

14.5 Nevarnosti za okolje

Nenevarno blago

14.6 Posebni previdnostni

ukrepi za uporabnika

Nenevarno blago

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II k

MARPOL 73/78 in Kodeksom

Nenevarno blago

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

v skladu z Uredbo o

detergentih ES 648/2004

30 % in več: Anionske površinsko aktivne snovi

Nacionalni predpis

Upoštevajte direktivo 94/33/ES za varnost in zdravje pri delu mladoletnih oseb.

Razred skladiščenja

Drugi predpisi

Zakon o kemikalijah

Pravilnik o tehničnih in organizacijskih ukrepih za skladiščenje

nevarnih kemikalij

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti rakotvornim ali mutagenim snovem

Pravilnik o osebni varovalni opremi, ki jo delavci uporabljajo pri

delu

Pravilnik o varovanju zdravja pri delu otrok, mladostnikov in

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

13 / 15

mladih oseb

Pravilnik o varovanju zdravja pri delu nosečih delavk, delavk, ki so

pred kratkim rodile ter doječih

Zakon o varstvu okolja

Uredba o odpadkih

Uredba o ravnanju z embalažo in odpadno embalažo

Zakon o prevozu nevarnega blaga

15.2 Ocena kemijske varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

ODDELEK 16: Drugi podatki

Celotno besedilo R-stavkov

Zdravju škodljivo pri zaužitju.

Draži oči.

Draži kožo.

Nevarnost hudih poškodb oči.

R51/53

Strupeno za vodne organizme, lahko povzroči dolgotrajne škodljive

učinke na vodno okolje.

R52/53

Škodljivo za vodne organizme, lahko povzroči dolgotrajne škodljive

učinke na vodno okolje.

Zdravju škodljivo: pri zaužitju lahko povzroci poškodbo pljuc.

Celotno besedilo H-stavkov

H290

Lahko je jedko za kovine.

H302

Zdravju škodljivo pri zaužitju.

H304

Pri zaužitju in vstopu v dihalne poti je lahko smrtno.

H315

Povzroča draženje kože

H318

Povzroča hude poškodbe oči.

H319

Povzroča hudo draženje oči.

H410

Zelo strupeno za vodne organizme, z dolgotrajnimi učinki.

H412

Škodljivo za vodne organizme, z dolgotrajnimi učinki.

Celotno besedilo drugih okrajšav

Pripravil

Regulatory Affairs

Števila navedena v varnostnem listu so podana v obliki: 1,000, 000=1 milijon in 1,000=1 tisoč. 0.1

= 1 deseti in 0.001 = 1 tisoči.

SPREMEMBE PODATKOV: Pomembne spremembe podatkov o predpisih in zdravju pri tej

popravljeni izdaji so nakazane s crto ob levem robu varnostnega lista.

Informacija v tem Varnostnem podatkovnem listu je pravilna po našem najboljšem znanju,

informacijah in prepričanju na dan njegove objave. Informacija je zasnovana samo kot napotilo za

varno rokovanje, uporabo, obdelavo/predelavo, shranjevanje/skladiščenje, transport,

odstranjevanje in izpust in ne sme biti interpretirana kot specifikacija jamstev in kakovosti.

Informacija se nanaša samo na označeni specifični material in morda ne bo veljavna za tak

material, če bo uporabljen v kombinaciji s kakšnim drugim materialom ali postopkom, razen če to

ni posebej navedeno v tekstu.

PRILOGA: SCENARIJI IZPOSTAVLJENOSTI

Snovi po DPD+:

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

14 / 15

:

Naslednje snovi so glavne sestavine, ki prispevajo k scenariju izpostavljenosti za zmesi, skladno z

metodologijo DPD+:

Pot

Snov

Št. CAS

Št. EINECS

Zaužitje

Benzensulfonska kislina, C10-13-alkil

derivati, natrijeve soli

68411-30-3

270-115-0

Vdihavanje

Ni snovi v sledeh

Kožno

Benzensulfonska kislina, C10-13-alkil

derivati, natrijeve soli

68411-30-3

270-115-0

Oči

Benzensulfonska kislina, C10-13-alkil

derivati, natrijeve soli

68411-30-3

270-115-0

vodno okolje

Benzensulfonska kislina, C10-13-alkil

derivati, natrijeve soli

68411-30-3

270-115-0

Fizikalne lastnosti snovi po DPD+:

Snov

Parni tlak

Topnost v vodi

Pow

Molska masa

Benzensulfonska kislina,

C10-13-alkil derivati,

natrijeve soli

< 0.0000001 Pa

0.1 g/l

Za preračun, ali so vaši nadaljnji pogoji obratovanja in ukrepi za obvladovanje tveganja varni,

prosimo, izračunajte faktor tveganja na spodaj navedeni spletni strani:

www.ecetoc.org/tra

Kratek naslov scenarija

izpostavljenosti

Čistilo za sanitarije. Ročni postopek

Deskriptorji uporabe

Glavne skupine uporabnikov

Poklicne uporabe: javna uporaba (uprava, izobraževanje,

razvedrilo, storitve, obrt)

Sektorji končne uporabe

SU22: Poklicne uporabe: javna uporaba (uprava, izobraževanje,

razvedrilo, storitve, obrt)

Skupine postopkov

PROC10: Nanašanje z valjčkom ali čopičem

PROC8a: Prenos snovi ali pripravka (polnjenje/ praznjenje) iz/ v

posode/ velike vsebnike na nenamenskih napravah

Kategorije izdelka

PC35: Izdelki za pranje in čiščenje (vključno z izdelki na osnovi

topil)

Kategorije sproščanja v

okolje

ERC8a: Močno razpršena notranja uporaba procesnih

pripomočkov v odprtih sistemih

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

Eco-clin urinal tablets

113462E

15 / 15

13-11-2018

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA published draft guidance for industry #243 “Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing MRLs and Withdrawal Periods.”

FDA - U.S. Food and Drug Administration

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

7-11-2018

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Vita Health Products is voluntarily recalling several store-brand (Care, Exact, Life, and Pharmasave) over-the-counter drugs used for pain or sinus relief because of a labelling issue. Consumers may be unable to peel open the wrap-around label on the bottle to access the warning statements, or the label may not peel off completely, which may make it difficult to read some of the important safety information.

Health Canada

6-11-2018

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Published on: Fri, 02 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the Australian Government Department of Agriculture and Water Resources submitted two requests to the competent national authority in Denmark to set import tolerances for the active substance haloxyfop‐P in linseed and rapeseed. The data submitted in support of the request were found to be sufficient to derive maximum residue level (MRL) proposals for linseed and rapeseed. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority Publications

3-11-2018

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Pharmaceuticals, Inc. has initiated a voluntary recall of one lot of ORTHO-NOVUM 1/35 (norethindrone / ethinyl estradiol) Tablets and two lots of ORTHO-NOVUM 7/7/7 (norethindrone / ethinyl estradiol) Tablets to the pharmacy level. The patient information provided inside affected packages of ORTHO-NOVUM does not include the appropriate instructions for the Veridate dispenser.

FDA - U.S. Food and Drug Administration

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

10-10-2018

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

The health risks associated with exposure to artificial UV radiation from tanning booths have been well established for many years now. ANSES points out that recent data on the subject support previous assessments: there is a proven cancer risk associated with UV radiation from artificial tanning equipment. The Agency therefore recommends that the public authorities take the necessary steps to prevent people from being exposed to artificial UV radiation from tanning booths used for cosmetic purposes.

France - Agence Nationale du Médicament Vétérinaire

28-9-2018

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily." (see pic...

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

Scientific guideline: Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

This document provides a standard approach to be used across the European Union in the analysis of residue depletion data for the purpose of establishing withdrawal periods for edible tissues. Emphasis has been put on a statistical approach. As the method of first choice, a linear regression technique is recommended. A computerised version of the method described is available: Updated application software: withdrawal time calculation for tissues. Read together with the explanatory note on updated applica...

Europe - EFSA - European Food Safety Authority EFSA Journal

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

31-8-2018

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA is warning the public about a voluntary recall of one lot of montelukast sodium tablets made by Camber Pharmaceuticals due to incorrect drug in bottles

FDA - U.S. Food and Drug Administration

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EFSA Panel on Plant Protection Products and their Residues reviewed the guidance on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessment. The inclusion of aged sorption is a higher tier in the groundwater leaching assessment. The Panel based its review on a test with three substances taken from a data set provided by the European Crop Protection Association. Particular points of attention were the quali...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 This report describes the framework of collection, management and transmission of food safety data in the Federal Republic of Germany. To adjust optimally the data governance processes to the requirements defined by the EFSA, measures had been agreed upon in order to improve the specified situation. Subsequent methodological system enhancements related to data quality are given as well as structural adjustments and the development and implementation of suppo...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

The EU's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted new recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones (bone metastases). Xofigo should only be used in symptomatic patients who have had two previous treatments for prostate cancer and who cannot be treated with other medicines.

Danish Medicines Agency

28-8-2018

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market.

FDA - U.S. Food and Drug Administration

23-8-2018

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

22-8-2018

Germany Niubian tablets

Germany Niubian tablets

Germany Niubian tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

22-8-2018

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industr...

FDA - U.S. Food and Drug Administration

18-8-2018

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probabl...

FDA - U.S. Food and Drug Administration

15-8-2018

G Female Oral Tablets

G Female Oral Tablets

G Female Oral Tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

6-8-2018

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment drugs to treat opioid use disorder.

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

27-7-2018

Pending EC decision:  Xerava, eravacycline, Opinion date: 26-Jul-2018

Pending EC decision: Xerava, eravacycline, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

20-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

FDA posted a new batch of 43 product-specific guidances related to the development of generic drug products that includes three revised product-specific guidances for ADF opioid products. These guidances recommend specific in vivo studies and in vitro study considerations for abuse deterrence evaluations.

FDA - U.S. Food and Drug Administration

19-7-2018

Assessment of the safety of feminine hygiene products

Assessment of the safety of feminine hygiene products

Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...

France - Agence Nationale du Médicament Vétérinaire

18-7-2018

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

In a context where prevention of ambient air pollution is a real public health issue, questions are regularly asked about the value of recommending that the population wear personal protective equipment. This led ANSES to assess the potential health benefits of wearing "anti-pollution" masks. Its expert appraisal revealed a lack of data demonstrating a health benefit. To reduce the health impacts associated with ambient air pollution, the Agency reiterates the importance of prioritising action at the sou...

France - Agence Nationale du Médicament Vétérinaire

17-7-2018

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical. The impurity detected in the API is N- nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking wat...

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

4-7-2018

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Cases of skin allergies and irritation related to clothing or footwear are regularly reported to the health authorities. Today ANSES is publishing the results of the expert appraisal it conducted to identify the chemicals likely to be found in these articles and possibly responsible for these cases. Further to this expert appraisal, the Agency is issuing recommendations on how to better protect consumers from the risks of skin allergies and irritation caused by the presence of these substances.

France - Agence Nationale du Médicament Vétérinaire

21-10-2018

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting  ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting https://go.usa.gov/xPnyd .

FDA - U.S. Food and Drug Administration

21-10-2018

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%, up from 84% in 1995.

FDA - U.S. Food and Drug Administration

9-10-2018

#ICYMI - FDA issues recommendations to help prevent surgical fires and      related patient injury. Click the link to read the recommendations:  https://go.usa.gov/xQdwG   #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

FDA - U.S. Food and Drug Administration

1-10-2018

IONSYS (Incline Therapeutics Europe Ltd)

IONSYS (Incline Therapeutics Europe Ltd)

IONSYS (Active substance: fentanyl) - Centralised - Withdrawal - Commission Decision (2018)6412 of Mon, 01 Oct 2018

Europe -DG Health and Food Safety

24-9-2018

Xerava (Tetraphase Pharmaceuticals Ireland Limited)

Xerava (Tetraphase Pharmaceuticals Ireland Limited)

Xerava (Active substance: Eravacycline) - Centralised - Authorisation - Commission Decision (2018)6231 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4237

Europe -DG Health and Food Safety

21-9-2018

Click the link for a handy list of #FDA’s recommendations for using and  caring for your medical devices during a #hurricane.   https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

15-8-2018

Scientific guideline:  Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) - Revision 1, draft: consultation open

Scientific guideline: Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) - Revision 1, draft: consultation open

The proposed guideline will replace annex to guideline on similar medicinal products containing biotechnology-derived proteins as active substance: Non-Clinical and Clinical Issues - Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor, EMEA/CHMP/BMWP/31329/2005

Europe - EMA - European Medicines Agency

6-8-2018

Scientific guideline:  ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

Scientific guideline: ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide rec...

Europe - EMA - European Medicines Agency

1-8-2018

Tygacil (Pfizer Europe MA EEIG)

Tygacil (Pfizer Europe MA EEIG)

Tygacil (Active substance: Tigecycline) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5218 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/644/T/104

Europe -DG Health and Food Safety

31-7-2018

Scientific guideline:  Draft guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells, draft: consultation open

Scientific guideline: Draft guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells, draft: consultation open

This guideline defines scientific principles and provides guidance for the development and evaluation of medicinal products containing genetically modified cells intended for use in humans and presented for marketing authorisation. Its focus is on the quality, nonclinical aspects and safety and efficacy requirements of genetically modified cells developed as medicinal products.

Europe - EMA - European Medicines Agency

18-7-2018

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity:  https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://healthsectorcouncil.org/health-sector-mobilizes-against-cyber-threats/ …

FDA - U.S. Food and Drug Administration

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

29-6-2018

Smoking among adolescents has declined but #ecigarette use is growing in popularity. See trends on teen #tobacco use and regulation efforts  http://bit.ly/1EE2lpG  via @TeenHealthGov

Smoking among adolescents has declined but #ecigarette use is growing in popularity. See trends on teen #tobacco use and regulation efforts http://bit.ly/1EE2lpG  via @TeenHealthGov

Smoking among adolescents has declined but #ecigarette use is growing in popularity. See trends on teen #tobacco use and regulation efforts http://bit.ly/1EE2lpG  via @TeenHealthGov

FDA - U.S. Food and Drug Administration